Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Eur J Cancer 2019 02 14;108:120-128. Epub 2019 Jan 14.

Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO and CiberOnc, Madrid, Spain. Electronic address:

Introduction: Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with previously treated advanced non-small cell lung cancer (NSCLC). This phase 2 trial examined second-line pembrolizumab + CC-486 (oral azacitidine) in patients with advanced NSCLC.

Methods: Patients with one prior line of platinum-containing therapy were randomised in a ratio of 1:1 to CC-486 or placebo, on days 1-14, in combination with pembrolizumab on day 1 of a 21-day cycle. The primary end-point was progression-free survival (PFS). Key secondary end-points included overall survival (OS), overall response rate (ORR) and safety.

Results: Among 100 patients randomised (pembrolizumab + CC-486: 51; pembrolizumab + placebo: 49), most were male (57.0%), were white (87.0%) and had Eastern Cooperative Oncology Group performance status 1 (68.0%). No significant difference in PFS was observed between the pembrolizumab + CC-486 and pembrolizumab + placebo arms (median, 2.9 and 4.0 months, respectively; hazard ratio [HR], 1.374; 90% confidence interval [CI], 0.926-2.038; P = 0.1789). Median OS was 11.9 months versus not estimable (HR, 1.375; 90% CI, 0.830-2.276; P = 0.2968); ORR was 20% versus 14%. Median treatment duration was shorter (15.0 versus 24.1 weeks), and the number of cycles was lower (5.0 versus 7.0) with pembrolizumab + CC-486 versus pembrolizumab + placebo. No new safety signals for CC-486 or pembrolizumab were detected. Treatment-emergent adverse events were more common in the pembrolizumab + CC-486 arm, particularly gastrointestinal, potentially impacting treatment feasibility.

Conclusions: No improvement in PFS was observed with pembrolizumab + CC-486 versus pembrolizumab + placebo. Decreased treatment exposure due to adverse events may have impacted efficacy with pembrolizumab + CC-486.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183153
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.11.028DOI Listing
February 2019
29 Reads

Publication Analysis

Top Keywords

non-small cell
8
advanced non-small
8
pembrolizumab + cc-486 pembrolizumab + placebo
8
treated advanced
8
adverse events
8
cell lung
8
versus pembrolizumab + placebo
8
pfs observed
8
observed pembrolizumab + cc-486
8
lung cancer
8
pembrolizumab + cc-486 versus
8
patients treated
8
pembrolizumab + cc-486
7
versus
7
patients
5
0926-2038 p = 01789
4
pembrolizumab + placebo arms
4
p = 01789 median
4
680% difference
4
median 119
4

Similar Publications